FDA Approves Italfarmaco SpA’s Duvyzat for Duchenne Muscular Dystrophy
March 22nd 2024Duvyzat (givinostat) is histone deacetylase inhibitor that was previously granted priority review, orphan drug designation, and rare pediatric disease designation by the FDA for patients 6 years of age and older with Duchenne muscular dystrophy.
Combining Cutting-Edge Technologies with Traditional Marketing
March 20th 2024In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, talks about how he has successfully combined cutting-edge technologies with traditional marketing approaches in his past ventures.
FDA Approves Johnson & Johnson’s Edurant PED for Pediatric Patients With HIV
March 20th 2024Expanded indication for Edurant in combination with other antiretroviral therapies includes treatment-naïve children with HIV-1 RNA <100,000 copies/mL aged at least 2 years and weighing between 14 kg and 25 kg.
Utilizing Generative AI for Rapid Content Creation and Distribution
March 19th 2024In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, explains utilizing generative AI for rapid content creation and how AI-driven automation of that content distribution has increased visibility.